The Food and Drug Administration gave Leqembi full approval last summer for patients with early stages of the disease. But sales have lagged. Original article: https://www.reviewjournal.com/livewell/its-the-1st-drug-shown-to-slow-alzheimers-why-is-it-off-to-a-slow-start-3036907/
